Dinara Ryspayeva

Grateful to Dr. Dinara Ryspayeva for presenting the manuscript on PPAR-delta as a prognostic biomarker and its association with immune infiltrates in breast cancer PPAR-delta as a prognostic biomarker and its association with immune infiltrates in breast cancer at #eldeirylab meeting at #LegorretaCancerCenter @BrownMedicine @Dina_rys

Register for the “Breast Cancer: New Horizons, Current Controversies” Course on July 17-18 – Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc @harvardmed oncodaily.com/blog/breast-ca… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedEd #MedNews #breastcancer @CancerWorldmag

Multiple studies looking at neoadjuvant regimens for HER2+ early BC. Looks like THP would suffice for most stage 1 and 2, and Cb not needed. Interesting question as to whether 6 cycles / 18 weeks is > than 4 cycles / 12 weeks. @ASCO #ASCO25 @OncoAlert

The #ASCO25 #OncoAlertTOP10 Abstracts in #BreastCancer These are some of our picks of TOP abstracts we look forward to be presented at ASCO HERE in Chicago🇺🇸 ⭐ LBA1008: DESTINY-BREASTO9: TRASTUZUMAB DERUXTECAN (T-DXD) + PERTUZUMAB (P) VS TAXANE + TRASTUZUMAB +PERTUZUMAB (THP) FOR FIRST-LINE (1L) TREATMENT OF HER2+ ADVANCED/METASTATIC BREAST CANCER ⭐LBA4: SERENA-6: CAMIZESTRANT + CDK4/61 IN EMERGENT ESR1 MUTATIONS DURING 1L ET & AHEAD OF DISEASE PROGRESSION IN HR+/HER2- ADV. BREAST CANCER ⭐LBA109: ASCENT-04/KEYNOTE-D19:SACITUZUMAB GOVITECAN + PEMBROLIZUMAB VS CHEMOTHERAPY +PEMBRO IN UNTREATED PD-L1+ ADVANCED TNBC ⭐LBA509:NRG-BRO03:COMPARING DOXORUBICIN PLUS CYCLOPHOSPHAMIDE FOLLOWED BY WEEKLY PACLITAXEL WITH OR W/O CARBOPLATIN FOR NODE+ OR HIGH-RISK NODE-NEGATIVE TNBC ⭐LBA500: NEOCARHP: DE-ESCALATED NEOADJUVANT TAXANE PLUS TRASTUZUMAB AND PERTUZUMAB WITH OR WITHOUT CARBOPLATIN IN HER2-POSITIVE EARLY BREAST CANCER ⭐505: SOFT AND TEXT: ASSESSING BENEFITS FROM ADJUVANT EXEMESTANE + OVARIAN FUNCTION SUPPRESSION OR TAMOXIFEN +OFS. ⭐LBA1005: CCTG/BCT MA.40/FINER: FULVESTRANT AND IPATASERTIB AS TREATMENT FOR ADVANCED HER2- AND ER+ BREAST CANCER FOLLOWING PROGRESSION ON 1L CDK 4/6 INH & AI ⭐LBA1000: VERITAC- 2: VEPDEGESTRANT, A PROTAC ESTROGEN RECEPTOR (ER) DEGRADER, VS FULVESTRANT IN ER+/HER2- ADVANCED BREAST CANCER ⭐1003: INAVO120: 1L INAVOLISIB/PLACEBO + PALBOCICLIB + FULVESTRANT IN PIKCA-MUTATED, HR+, HER2-, ENDOCRINE-RESISTANT ADVANCED BREAST CANCER (ABC). ⭐2005: TUXEDO-3: PATRITUMAB DERUXTECAN (HER3-DXD) IN ACTIVE BRAIN METASTASES (BM) FROM METASTATIC BREAST (MBC) AND NON-SMALL CELL LUNG CANCERS (ANSCLC), AND LEPTOMENINGEAL DISEASE (LMD) FROM ADVANCED SOLID TUMORS ⭐508: OASIS 4: EFFICACY AND SAFETY OF ELINZANETANT FOR VASOMOTOR SYMPTOMS ASSOCIATED WITH ADJUVANT ENDOCRINE THERAPY LEADS: @ElisaAgostinett @to_be_elizabeth @WeOncologists Senior Faculty: @matteolambe @E_de_Azambuja @ErikaHamilton9 Fatima Cardoso @ABCGlobalAll @maryam_lustberg @hoperugo Co Leads: @GaiaGriguolo @JankovicK Breast cancer Faculty @aftimosp @NicoleKuderer @FAndreMD @prat_aleix @DrSGraff @jesusanampa @double_whammied @stage4kelly @coffeemommy @itsnot_pink @IBCResearch @kevinpunie @nicolobattisti @raalbany @stolaney1 @LoiSher @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @paspears88 @MammaMiaMagazin @itrisabel #OncoAlertAF @nataliagandur @acampsmalea @BRicciutiMD @yekeduz_emre @HHorinouchi @FadiHaddad_MD @Dr_Ivanoncologo @Abdallah81MD @FernandoOnco @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco

Now is oficial Dr. @stolaney1 will present the primary results of DB09 on June 2nd at Hall D1 at 7:30am #asco25

Delighted to share 25 presentations from #LegorretaCancerCenter at #AACR25 Very proud of our collaborating scientists and physicians who are having impact in Rhode Island and beyond. I am personally proud of the >20 #eldeirylab contributions on my 30th year of @AACR membership

@tajiknia @weldeiry @BrownUCancer @SheldonLHolder @TheNRMP You got it! Congratulations!

#Match2025 I am thrilled that I get to stay in #RhodeIsland for my training where my family and mentors are! Beyond grateful! @weldeiry Thank you for your support to all my mentors and my fiancé! @BrownUCancer @SheldonLHolder @TheNRMP

Congrats to @Dina_rys and colleagues at #LegorretaCancerCenter @BrownMedicine @BrownUnivHealth on publishing review: Signaling pathway dysregulation in breast cancer pubmed.ncbi.nlm.nih.gov/40080721/ @DrMartyTaylor @DrSGraff @LiangChengMD @rwsobol @bcarneiro7 @SeanLawler20 @SenduraiMani

Wonderful for us all to get together for the LCC Immunology and Cancer Biology Mini-Symposium @BrownUCancer @BrownUniversity @weldeiry @BrownUResearch @BrownMedicine

It was a wonderful surprise ⁦@tajiknia⁩

📌5 Must-read Articles suggested by Wafik El-Deiry (@weldeiry) oncodaily.com/url/228812 ✍️@drraghibali @BrodinPetter @MPercharde @VirinderReen @PinhoSchwermann #Cancer #CancerResearch #MedEd #MedX #MedNews #Health #Medicine #OncoDaily #Oncology

We are thrilled to have Dr. Roy Herbst @DrRoyHerbstYale @YaleCancer @YaleMed visit with us at Brown University for Department of Medicine Grand Rounds/Paul Calabresi Lecture and an invited lecture at the #LegorretaCancerCenter @BrownUCancer @BrownMedicine @BrownUniversity @BrownUnivHealth Dr Herbst is a giant in the field of oncology clinical trials in lung cancer.

Findings from a recent MD Anderson study question conventional thinking on the genetic origins of breast cancer, which could influence early cancer detection methods. Learn more: brnw.ch/21wOOZz @nicholas_navin #EndCancer

Dear #ESMO24 We Are HERE WE ARE @OncoAlert 🚨 @weoncologists @montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas @yekeduz_emre @DrYukselUrun

PPARβ/δ-orchestrated metabolic reprogramming supports the formation and maintenance of memory CD8+ T cells “Bevilacqua et al. found that the nuclear receptor peroxisome proliferator–activated receptor β/δ (PPARβ/δ) supports the switch from aerobic glycolysis to oxidative metabolism during central memory CD8+T cell formation.” science.org/doi/10.1126/sc… @Dina_rys

Learning from Dr. Ghandali at #eldeirylab meeting about osteoclast targeting to address PARP inhibitor resistance in breast cancer. @BrownUCancer @BrownMedicine @BrownUniversity @rwsobol @SenduraiMani @DrSGraff @drdonsdizon @bcarneiro7 @Dina_rys

@Dina_rys great to have our Ukrainian friends with us! 🇺🇦 @BrownUCancer #AACR24 #AACRChallenge

Honored to join Ukrainian delegation including #eldeirylab physician-scientist oncologist members Dinara Ryspayeva and Nataliia Verovkina as they met with @JimAllisonPhD and @PamSharmaMDPhD after @CarolynBertozzi’s presentation this morning @AACR’s plenary session @AACR #AACR24 @Dina_rys @BrownUniversity #eldeirylab @BrownUCancer @ShiOnaCo @VivekSubbiah @christine_lovly @DrRoyHerbstYale @CharlesSwanton @mpdrc @do_phd @jrgralow @theNCI @NCIDirector @AACR_CEO @AACRPres @MDAndersonNews @BrownPathology @BrownMedicine @SheldonLHolder @DrSGraff @drdonsdizon @bcarneiro7 @rwsobol @SenduraiMani @Dr_R_Kurzrock @WIN_Consortium @drKMusallam

Such a nice surprise to see our friend, Dr. Bob Weinberg as he stopped by the medical school holiday reception this evening. Thankful to @SenduraiMani for hosting him and always great to have conversations with Bob. @BrownMedicine @MIT #LegorretaCancerCenter @ShiOnaCo @BrownUniversity @rwsobol @drdonsdizon @LiangChengMD @AmericanCancer @Dina_rys @theNCI @tajiknia @SeanLawler20

Thanks to Professor ⁦⁦Wafik El-Deiry⁩ and the training in the ⁦⁦@weldeiry⁩ lab ⁦@BrownUCancer⁩ this data has become clear and I now understand how to implement it into clinical practice. @SABCSSanAntonio #SABCS23